Lexicon Pharmaceuticals (NASDAQ:LXRX) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release. Analysts ...

Shares of Lexicon Pharmaceuticals tanked nearly 33.6% as of 11:30 am ET after the drug company’s sotagliflozin drug candidate received a negative vote by a US Food and Drug Administration (FDA ...

Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.45. The firm has a market cap of $140.48 million, a price-to-earnings ratio of -0.76 and a beta of 1.04.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript May 13, 2025 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.1.

Lexicon Pharmaceuticals shares are trading lower by 48% Monday morning. The company earlier announced topline results from its PROGRESS Phase 2b study evaluating pilavapadin. Ready to turn the ...

Texas-based biotech Lexicon Pharmaceuticals (NASDAQ:LXRX) was incorporated in 1995, and has been listed on the Nasdaq since 2000. According to a statement in the company's 2022 10K submission ...

Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and ...

Lexicon Pharmaceuticals, Inc. announced a conference call and webcast scheduled for March 3, 2025, at 8:00 a.m. ET to discuss topline results from the Phase 2b PROGRESS study of pilavapadin ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced topline results from the PROGRESS Phase 2b study evaluating pilavapadin (LX9211), an oral, non-opioid investigational adaptor ...

Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa ...

Nov 22 (Reuters) - Lexicon Pharmaceuticals (LXRX.O), opens new tab said on Friday it would reduce its workforce by about 60%, after the U.S. Food and Drug Administration noted deficiencies in its ...